Questions to Ask Your Doctor About Medical Weight Loss

Why Your Questions Matter

Medical weight loss is not one treatment. A visit may involve reviewing whether you have obesity or overweight with a weight-related health condition, discussing previous attempts to lose weight, and considering lifestyle care, medication, a procedure, or surgery. The right approach depends on your health, treatment history, goals, preferences, and the risks associated with each option.

Behavioral care is an important part of this conversation. The U.S. Preventive Services Task Force recommends offering or referring adults with a BMI of 30 or higher to intensive, multicomponent behavioral interventions. These interventions may address nutrition, physical activity, goal setting, self-monitoring, barriers, and maintenance. The American Gastroenterological Association recommends adding medication to lifestyle interventions for appropriate adults who have not had an adequate response to lifestyle measures alone.

These recommendations provide a framework, not an automatic treatment decision. BMI does not fully describe body composition, metabolic risk, function, or personal priorities. A useful appointment should therefore move beyond “Do I qualify?” to “Why does this option make sense for me?” Reviewing the broader Medical Weight Loss care pathway before your visit can help you identify the topics you want to discuss.

Once a particular medication is proposed, ask for its generic and brand names, approved use, dosing schedule, and current prescribing instructions. If doses are increased over time, ask how that process works and whom to contact if you cannot tolerate the planned increase. Do not assume that instructions for one injectable or oral medicine apply to another.

The AGA guideline conditionally suggests semaglutide, liraglutide, phentermine-topiramate extended release, naltrexone-bupropion extended release, phentermine, and diethylpropion alongside lifestyle intervention for appropriate adults. This list does not mean that the medicines have equal effectiveness, risks, or suitability. Selection should reflect the individual medication’s contraindications and precautions as well as your health history, preferences, and ability to access treatment.

Pregnancy plans must be discussed before treatment begins. General guidance states that weight-management medications should not be used during pregnancy or when planning pregnancy and are not recommended during breastfeeding. Exact instructions and discontinuation timing come from the label for the specific drug. For example, semaglutide labeling advises stopping it at least two months before a planned pregnancy for weight reduction. Ask what guidance applies to the medication being considered and what to do if pregnancy occurs.

Duration is another essential topic. Evidence from particular trials shows that weight regain can occur after withdrawal. In the STEP 1 extension, participants regained an average of 11.6 percentage points of body weight during the year after semaglutide was stopped-approximately two-thirds of their previous loss. In SURMOUNT-4, participants switched from tirzepatide to placebo regained about 14% over the next 52 weeks, while those continuing tirzepatide lost an additional 5.5%. These findings concern specific drugs and study populations; they do not predict every patient’s experience.

Ask how the treatment will be monitored and how your clinician will decide whether to continue, adjust, or stop it. The evidence supplied for this guide does not establish one follow-up schedule, laboratory panel, or stopping rule for every medication. A medical weight-loss evaluation can help organize the history and safety information needed for that discussion.

Ask the prescriber to identify the exact product being proposed: its name, formulation, dose, manufacturer when applicable, and whether it is FDA-approved or compounded. Do not treat the words “semaglutide” or “tirzepatide” alone as proof that two products have the same regulatory status or instructions.

A licensed pharmacy dispenses medications, but pharmacy licensure by itself does not establish that a particular product is FDA-approved. Product approval should be checked using the exact drug information and FDA resources. If the prescriber or dispensing service cannot clearly explain what you would receive, pause and request clarification. The goal is not to make assumptions about every compounded product; it is to understand that compounded and FDA-approved products are reviewed differently and should not be presented as equivalent.

Your clinician should also explain the prescribed measuring device and dosing units. FDA reports concerning compounded injectable products have included incorrect measurement, dose miscalculation, dosing more often than directed, and titration faster than instructed. Follow only the directions supplied for your exact prescription. For more context on supervised care, review medical weight-loss treatment options.

Metabolic and bariatric surgery may enter the conversation when BMI, metabolic disease, previous treatment, and overall health make a surgical assessment reasonable. The 2022 ASMBS/IFSO guideline recommends surgery for people with a BMI of at least 35 regardless of comorbidities and recommends considering it for selected people with metabolic disease and a BMI from 30 to 34.9. These specialty-society criteria may differ from older or more conservative patient-facing summaries.

BMI is not the entire assessment. Ask whether you need a multidisciplinary evaluation and what information the surgical team would review. The decision should account for your overall health and ability to participate in continuing care, rather than treating a threshold as an automatic recommendation.

NIDDK notes that metabolic and bariatric surgery can improve obesity-related health problems, but it can also have immediate and later-emerging side effects and may require follow-up procedures or long-term monitoring. Ask what benefits are expected for your situation, what operative and nutritional risks should be considered, and what follow-up would be required.

If surgery is not recommended, ask your clinician to explain the reasoning. If it is recommended, ask how it compares with nonsurgical options in your case. A clear comparison should address the expected care process, risks, follow-up responsibilities, and how each choice aligns with your priorities.

Maintenance should be discussed before treatment starts, not only when a prescription ends or progress slows. Lifestyle change is generally the foundation of weight management, and the USPSTF’s description of intensive behavioral care includes maintenance strategies. Medication-withdrawal trials also show why it is important to ask what may happen if a particular treatment is stopped.

A useful long-term plan explains how progress will be reviewed, what continuing support is available, and what options may be discussed if treatment is ineffective, poorly tolerated, inaccessible, or no longer appropriate. Because evidence and labeling vary by treatment, the answers should be specific to your plan.

• Is this treatment intended to continue long term? Ask about the proposed duration and how the clinician will reassess benefits and risks.
• What is the plan if I stop? Ask what follow-up or alternative care would be considered. Do not assume that evidence from semaglutide or tirzepatide withdrawal applies identically to every medication.
• How will progress and safety be reviewed? Request a schedule tailored to the treatment, your health history, and the current prescribing information.
• What behavioral support is available? Ask whether nutrition, physical activity, goal setting, self-monitoring, barrier management, and maintenance support are included.
• What if access changes? Ask whom to contact if coverage or availability changes rather than changing the dose, substituting a product, or stopping on your own.

• Write down your priorities. Decide whether your main questions concern eligibility, treatment choices, side effects, pregnancy planning, monitoring, surgery, or maintenance.
• Bring a complete medication list. Include prescriptions, nonprescription medicines, supplements, and compounded products, along with the doses you use.
• Summarize your weight and treatment history. Note previous lifestyle programs, medications, or procedures and what happened while you used them.
• Share relevant medical and family history. Contraindications and precautions differ by drug, so your clinician needs accurate information before making a recommendation.
• Discuss pregnancy and breastfeeding directly. Ask about the guidance and timing for the exact treatment under consideration rather than applying one medication’s instructions to every drug.
• Request written, product-specific directions. Before leaving, confirm the dose, schedule, monitoring plan, side-effect instructions, and contact route for questions between appointments.